Immuneering Corp. (IMRX)
4.58
-0.20
(-4.18%)
USD |
NASDAQ |
Sep 09, 15:46
Immuneering Total Assets (Quarterly) : 202.06M for June 30, 2026
Total Assets (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Total Assets (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 202.06M |
| March 31, 2026 | 214.81M |
| December 31, 2025 | 231.98M |
| September 30, 2025 | 241.06M |
| June 30, 2025 | 40.06M |
| March 31, 2025 | 50.68M |
| December 31, 2024 | 52.71M |
| September 30, 2024 | 68.56M |
| June 30, 2024 | 77.09M |
| March 31, 2024 | 87.98M |
| December 31, 2023 | 102.58M |
| September 30, 2023 | 113.88M |
| Date | Value |
|---|---|
| June 30, 2023 | 124.90M |
| March 31, 2023 | 107.70M |
| December 31, 2022 | 122.37M |
| September 30, 2022 | 133.69M |
| June 30, 2022 | 142.05M |
| March 31, 2022 | 152.45M |
| December 31, 2021 | 166.70M |
| September 30, 2021 | 164.04M |
| June 30, 2021 | 53.04M |
| March 31, 2021 | 32.86M |
| December 31, 2020 | 38.47M |
Total Assets Definition
Assets are a main portion of the balance sheet of a company that measure things that provide economic value. A few examples of assets of a company include cash, inventories, and accounts receivable. From an accounting perspective, the balance sheet equation is Assets = Liabilities + Shareholder's Equity.
Total Assets (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Total Assets (Quarterly) Benchmarks
| Regeneron Pharmaceuticals, Inc. | 41.73B |
| ACADIA Pharmaceuticals, Inc. | 1.743B |
| Alnylam Pharmaceuticals, Inc. | 5.559B |
| Anika Therapeutics, Inc. | 183.47M |
| Savara, Inc. | 192.14M |
Total Assets (Quarterly) Related Metrics
| Total Liabilities (Quarterly) | 11.32M |
| Shareholders Equity (Quarterly) | 190.74M |
| Debt to Equity Ratio | 0.0191 |
| Current Ratio | 19.47 |
| Net Debt Paydown Yield | 0.03% |